Latest Breaking News On - Tom delahoyde - Page 1 : comparemela.com

Chiesi s Raxone recommended for use within NHS Wales 27th April 2021 Chiesi’s rare disease medicine Raxone has been recommended for use within NHS Wales for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON). LHON, a maternally inherited disease, is caused by a mutation in mitochondrial DNA that results in visual impairment. Although it can occur at any age, LHON commonly affects young men in their 20s and 30s. Raxone (idebenone) is believed to inhibit lipid peroxidation, protecting cell membranes and mitochondria from oxidative damage. According to the criteria in the All Wales Medicines Strategy Group (AWMSG) appraisal process, Raxone is considered an ultra-orphan medicine.

United kingdomNorthern irelandTom delahoydeWales medicines strategy groupHereditary optic neuropathyAll wales medicines strategy groupWales patient access schemeChiesi pharmaNhs walesஒன்றுபட்டது கிஂக்டம்வடக்கு ஐயர்ல்யாஂட்வேல்ஸ் மருந்துகள் மூலோபாயம் குழுபரம்பரை பார்வை நரம்பியல்அனைத்தும் வேல்ஸ் மருந்துகள் மூலோபாயம் குழுவேல்ஸ் நோயாளி நுழைவு திட்டம்க ரவ